DLL3xCD3xCD2 TsAb / Probio - LARVOL DELTA

A novel DLL3 trispecific T cell engager antibody integrating the CD2/CD58 co-stimulatory pathway demonstrates superior antitumor efficacy and balanced safety profile (AACR 2026) - "These challenges contribute to the narrow therapeutic window of TCEs in treating solid tumors and partially explain why no solid tumor-targeting TCE received regulatory approval until the DLL3-targeting tarlatamab became the first (and only to date) in 2024. In summary, the incorporation of a CD2 co-stimulatory moiety into a DLL3-targeting TCE leads to a novel, next-generation TCE with improved efficacy and safety profiles in preclinical studies. IND-enabling studies are ongoing with the potential to advance it to clinical studies in the near future."

Clinical • Trispecific • Hematological Malignancies • Oncology • Solid Tumor • CD2 • CD58 • DLL3 • TNFA